Launch of generic Myrbetriq ER (Mirabegron ER)

The generic formulation of Myrbetriq ER (Mirabegron ER) has been approved by the FDA. 

Mirabegron extended-release tablets are indicated for the treatment of OAB (overactive bladder) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. 

Mirabegron ER will be available in 25mg and 50mg tablets. The generic release of Myrbetriq ER (Mirabegron ER) is anticipated to launch in the second quarter of 2024. 

Mirabegron ER is manufactured by Zydus and Lupin Pharmaceuticals.